Drug Trial Radar · NCT04119050
Efficacy and Safety of M281 in Adults With Warm Autoimmune Hemolytic Anemia
Last checked: Nov 20, 2026Latest source record: Aug 31, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
118
Actual
Start
Aug 15, 2019
Primary completion
Feb 2, 2025
Study completion Apr 1, 2028
Sponsor
- Lead sponsor
- Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
- Sponsor type
- Industry
- First posted
- Oct 8, 2019
Design
- Study type
- Interventional
- Phase
- Phase 2 / Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The main purpose of this study is to evaluate the efficacy and safety of M281 in participants with warm autoimmune hemolytic anemia (wAIHA).
Conditions
- Warm Autoimmune Hemolytic Anemia
Interventions
M281Drug
M281 injection administered as intravenous infusion
PlaceboDrug
Placebo administered as intravenous infusion
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants Achieving Durable Response of Improvement in Hemoglobin (Hgb)Time frame: Up to Week 20 of the double-blind period
Locations
171 sites in 19 countries. Site status is shown where the registry gives one.
MemorialCare Medical Group
Fountain Valley, California
University of Southern California
Los Angeles, California
Compassionate Cancer Care
Riverside, California
American Institute of Research
Whittier, California
University of Colorado Anschutz Medical Campus
Aurora, Colorado
GNP Research
Cooper City, Florida
University of Florida College of Medicine
Gainesville, Florida
21st Century Oncology
Jacksonville, Florida
Lakes Research
Miami Lakes, Florida
AdventHealth Cancer Institute
Orlando, Florida
Children's Research Institute
St. Petersburg, Florida
Rush University Medical Center
Chicago, Illinois
Alliance for Multispeciality Research
Merriam, Kansas
Tulane University School of Medicine
New Orleans, Louisiana
Henry Ford Medical Center
Detroit, Michigan
Research Medical Center
Kansas City, Missouri
Montefiore Medical Center
Lake Success, New York
Monter Cancer Center
Lake Success, New York
Hematology Oncology Associates of Rockland
Nyack, New York
Duke University Medical Center
Durham, North Carolina
East Carolina University
Greenville, North Carolina
Taussig Cancer Insititute Cleveland Clinic
Cleveland, Ohio
The Ohio State University- James Cancer Hospital
Columbus, Ohio
Children's Hospital of Philadelphia
Philadelphia, Pennsylvania
Hospital of the University of Pennsylvania
Philadelphia, Pennsylvania
West Penn Hospital
Pittsburgh, Pennsylvania
University of Utah
Salt Lake City, Utah
Northwest Medical Specialists
Tacoma, Washington
University of Wisconsin Carbone Cancer Center
Madison, Wisconsin
Hospital das Clínicas da Faculdade de Medicina de Botucatu
Botucatu, Brazil
Impar Servicos Hospitalares S/A - Hospital Brasilia
Brasília, Brazil
CTO Centro de Tratamento Oncologico Unidade Belem
Campinas, Brazil
Hospital Das Clinicas Da Universidade Federal De Goias
Goiânia, Brazil
Complexo Hospitalar de Niteroi
Niterói, Brazil
Oncoclinicas - Unidade OC Oncoclinicas Multihemo Ilha do Leite
Recife, Brazil
Nucleo de Oncologia da Bahia
Salvador, Brazil
Hospital Sao Rafael
Salvador, Brazil
CEPHO Centro de Estudos e Pesquisa de Hematologia e Oncologia
Santo André, Brazil
Hospital Santa Marcelina
Santo André, Brazil
Fundacao Faculdade Regional de Medicina de Sao Jose do Rio Preto Hospital de Base
São José do Rio Preto, Brazil
Showing 40 of 171 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.